Galectin Therapeutics Inc. (GALT)

Galectin Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	17.72	15.12	25.66	18.59	39.65
Cash & Short-Term Investments	17.72	15.12	25.66	18.59	39.65
Cash Growth	17.20%	-41.08%	38.02%	-53.11%	46.08%
Other Current Assets	1.72	2.13	2.05	1.96	2.17
Total Current Assets	19.44	17.25	27.71	20.55	41.82
Net Property, Plant & Equipment	0.1	0.24	0.49	0.73	0.01
Total Assets	19.53	17.5	28.2	21.29	41.83
Accounts Payable	3.25	5.66	6.43	3.89	1.81
Accrued Expenses	4.72	8.2	9.18	9.06	7.16
Current Portion of Long-Term Debt	-	21.12	-	-	-
Other Current Liabilities	0.06	0.43	0.06	0.06	0.07
Total Current Liabilities	8.03	35.41	15.68	13.01	9.03
Long-Term Debt	133.74	85.11	71.74	39.83	29.05
Other Long-Term Liabilities	3.96	0.05	1.02	0.64	1.13
Total Long-Term Liabilities	137.7	85.16	72.77	40.47	30.18
Total Liabilities	145.73	120.57	88.44	53.48	39.21
Preferred Stock	0.49	0.5	0.5	0.51	0.53
Common Stock	0.07	0.06	0.06	0.06	0.06
Additional Paid-in Capital	304.07	296.22	291.85	275.08	271
Retained Earnings	-432.55	-401.57	-354.37	-309.57	-270.69
Total Common Shareholders' Equity	-127.92	-104.79	-61.96	-33.92	0.89
Minority Interest	1.72	1.72	1.72	1.72	1.72
Shareholders' Equity	-126.2	-103.07	-60.24	-32.19	2.62
Total Liabilities & Equity	19.53	17.5	28.2	21.29	41.83
Total Debt	133.74	106.23	71.74	39.83	29.05
Net Cash (Debt)	-116.02	-91.11	-46.08	-21.24	10.6
Net Cash Growth	-	-	-	-	-60.95%
Net Cash Per Share	-1.81	-1.46	-0.77	-0.36	0.18
Book Value	-127.92	-104.79	-61.96	-33.92	0.89
Book Value Per Share	-2.00	-1.68	-1.03	-0.57	0.02
Tangible Book Value	-127.92	-104.79	-61.96	-33.92	0.89
Tangible Book Value Per Share	-2.00	-1.68	-1.03	-0.57	0.02

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q